AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18711765 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine therapy (TCM)
Number of subjects: 396
Study 15715614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg of Ringer's acetate over 3 min
Number of subjects: 75
Study 15715614 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml/kg of low‐molecular weight (1 kDa) dextran over 3 min
Number of subjects: 75
Study 15715614 — intervention group
Group type: COMPARATOR
Intervention: 15 ml/kg of Ringer's acetate over 40 min
Number of subjects: 75
Study 11844036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) treatment
Number of subjects: 38
Study 11844036 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 38
Study 10414685 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential Reinforcement of Other Behavior (DRO)
Number of subjects: 15
Study 10414685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual Goal Setting (MGS)
Number of subjects: 15
Study 10414685 — intervention group
Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 15
Study 7582386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once a day
Number of subjects: 66
Study 7582386 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10‐40 mg once a day
Number of subjects: 66
Study 7582386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg once a day
Number of subjects: 66
Study 7582386 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 66
Study 2311339 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg administered orally) with food
Number of subjects: 12
Study 6772808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric regimen (47 ± 1 kcal/kg/day and 81 ± 4 kcal/kg/day)
Number of subjects: 10
Study 6772808 — intervention group
Group type: COMPARATOR
Intervention: Normocaloric regimen (47 ± 1 kcal/kg/day)
Number of subjects: 10
Study 6772808 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher energy:nitrogen ratio (230 ± 6)
Number of subjects: 10
Study 6772808 — intervention group
Group type: COMPARATOR
Intervention: Lower energy:nitrogen ratio (132 ± 4)
Number of subjects: 10
Study 6343629 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 189
Study 6343629 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum
Number of subjects: 189
Study 6343629 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate
Number of subjects: 189
Study 30118728 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised therapy with mometasone furoate (80% of students prescribed)
Number of subjects: 393
Study 30118728 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 393
Study 29437071 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR (chest radiograph) group
Number of subjects: 500
Study 29437071 — intervention group
Group type: COMPARATOR
Intervention: CT scan group
Number of subjects: 500
Study 29437071 — intervention group
Group type: COMPARATOR
Intervention: Three-monthly follow-up group
Number of subjects: 500
Study 29437071 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-monthly follow-up group
Number of subjects: 500
Study 27311491 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 404
Study 27311491 — intervention group
Group type: COMPARATOR
Intervention: Lixisenatide 20 µg
Number of subjects: 404
Study 27311491 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 404
Study 24377662 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES with 500 μs pulse duration
Number of subjects: 15
Study 24377662 — intervention group
Group type: COMPARATOR
Intervention: NMES with 200 μs pulse duration
Number of subjects: 15
Study 23173251 — intervention group
Group type: EXPERIMENTAL
Intervention: Danlou tablet (DT) + Western medicine
Number of subjects: 66
Study 23173251 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Control)
Number of subjects: 66
Study 20450927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 29.3mg THC
Number of subjects: 24
Study 20450927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 49.1mg THC
Number of subjects: 24
Study 20450927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes containing 69.4mg THC
Number of subjects: 24
Study 18020073 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg paracetamol
Number of subjects: 20
Study 18020073 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/kg paracetamol
Number of subjects: 20
Study 15960557 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate 50/500 microg twice daily
Number of subjects: 0
Study 15960557 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate with assumed survival benefit
Number of subjects: 0
Study 15960557 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate with a 10% improvement in forced expiratory volume
Number of subjects: 0
Study 15960557 — intervention group
Group type: COMPARATOR
Intervention: Usual care (placebo group)
Number of subjects: 0
Study 12389272 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke Free Families intervention
Number of subjects: 74
Study 12389272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 10660874 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ENDUROX
Number of subjects: 10
Study 10660874 — intervention group
Group type: COMPARATOR
Intervention: 400 mg placebo
Number of subjects: 10
Study 7558229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension and elevated low- to high-density lipoprotein cholesterol ratio (> 4.4)
Number of subjects: 2702
Study 7558229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2702
Study 7558229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 2702
Study 7558229 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous elevation of blood pressure and lipids
Number of subjects: 2702
Study 7558229 — intervention group
Group type: COMPARATOR
Intervention: No specific control group mentioned
Number of subjects: 2702
Study 2081954 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (Ca(OH)2 USP)
Number of subjects: 76
Study 2081954 — intervention group
Group type: EXPERIMENTAL
Intervention: Calasept
Number of subjects: 76
Study 2081954 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 76
Study 2081954 — intervention group
Group type: COMPARATOR
Intervention: Control group (not medicated)
Number of subjects: 76
Study 373425 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment (5 patients)
Number of subjects: 53
Study 373425 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (4 patients)
Number of subjects: 53
Study 31494943 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device (LVAD) therapy
Number of subjects: 5
Study 31494943 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pre‐LVAD proteome profiles of ICM with DCM
Number of subjects: 5
Study 30910804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 30910804 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 29074312 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl
Number of subjects: 35
Study 29074312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27647855 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta1 mAb (2‐, 10‐, or 50‐mg monthly subcutaneous dosing for 12 months)
Number of subjects: 416
Study 25010820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic protocol including fluid administration and vasoactive drugs based on arterial blood pressure, cardiac index, and stroke volume response
Number of subjects: 142
Study 25010820 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 142
Study 23016530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional microneedle radiofrequency (MRF) device
Number of subjects: 20
Study 23016530 — intervention group
Group type: COMPARATOR
Intervention: CO(2) fractional laser system (FS)
Number of subjects: 20
Study 19143532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (10 mg/kg per day in 4 divided doses for 7 days)
Number of subjects: 153
Study 19143532 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 153
Study 19143532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 153
Study 19143532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 17925072 — intervention group
Group type: EXPERIMENTAL
Intervention: Short waiting time (<or=3 months)
Number of subjects: 622
Study 17925072 — intervention group
Group type: COMPARATOR
Intervention: Non-fixed waiting time
Number of subjects: 622
Study 15123524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 279
Study 15123524 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 279
Study 15332779 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy
Number of subjects: 60
Study 15332779 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 9240884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus delivery of Curosurf (200 mg kg(‐1))
Number of subjects: 102
Study 9240884 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-hole delivery of Curosurf (200 mg kg(‐1))
Number of subjects: 102
Study 9240884 — intervention group
Group type: COMPARATOR
Intervention: Both bolus and side-hole delivery methods
Number of subjects: 102
Study 8275903 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 1 mg/kg/day
Number of subjects: 6
Study 8275903 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 0.5, 1, and 2 mg/kg/day
Number of subjects: 6
Study 8275903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3122164 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin‐releasing hormone (TRH) administered intravenously
Number of subjects: 9
Study 3122164 — intervention group
Group type: COMPARATOR
Intervention: Control (nondrug experimental conditions)
Number of subjects: 9
Study 31273577 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR antibody-drug conjugate (specific dosage and duration not mentioned)
Number of subjects: 3303
Study 27825963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed invitation for ultrasound screening examination
Number of subjects: 1800
Study 27825963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed invitation for ultrasound screening examination and patient navigation
Number of subjects: 1800
Study 27825963 — intervention group
Group type: COMPARATOR
Intervention: Usual care (visit-based screening)
Number of subjects: 1800
Study 26509943 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U)
Number of subjects: 250
Study 26509943 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (20 U)
Number of subjects: 250
Study 23761054 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac + Naltrexone (Group 1)
Number of subjects: 8
Study 23761054 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Naltrexone (Group 2)
Number of subjects: 8
Study 22167145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antidepressants (SSRIs) and cognitive behavioral therapy (CBT) for 6 weeks
Number of subjects: 19
Study 22167145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antidepressants (SSRIs) and cognitive behavioral therapy (CBT)
Number of subjects: 19
Study 22167145 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 19780375 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity respiratory muscle training (RMT) performed daily at approximately 90% PI(max) for 6 weeks with 2 x 30 breath cycles using an Ultrabreathe lung trainer
Number of subjects: 17
Study 19780375 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 17
Study 16829489 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall-to-reject
Number of subjects: 0
Study 16829489 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctiveness heuristic
Number of subjects: 0
Study 15810603 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuyutongmai (ZYTM) Capsule
Number of subjects: 64
Study 15810603 — intervention group
Group type: COMPARATOR
Intervention: Naoluotong
Number of subjects: 64
Study 11522557 — intervention group
Group type: COMPARATOR
Intervention: Calcium load of 0 and 25 mg/kg body weight taken at 0900 and 2100
Number of subjects: 30
Study 11522557 — intervention group
Group type: COMPARATOR
Intervention: Calcium load of 0, 250, and 1000 mg taken at 0900
Number of subjects: 30
Study 11522557 — intervention group
Group type: COMPARATOR
Intervention: Calcium load of 0 and 200 mg taken 4 times/day
Number of subjects: 30
Study 11522557 — intervention group
Group type: COMPARATOR
Intervention: Calcium loads of 0, 250, 1000 mg, and 200 mg taken at various times
Number of subjects: 30
Study 8986184 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infiltration before incision (group 1)
Number of subjects: 68
Study 8986184 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infiltration before incision (group 2)
Number of subjects: 68
Study 8986184 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infiltration after surgery (group 3)
Number of subjects: 68
Study 1358168 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral tamoxifen (480 or 720 mg day‐1 for 6 days beginning 3 days before etoposide)
Number of subjects: 26
Study 1358168 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (300 mg day‐1 for 3 days)
Number of subjects: 26
Study 1358168 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral tamoxifen
Number of subjects: 26
Study 1358168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen serum levels (3‐3.5 microM on day 4)
Number of subjects: 26
Study 6585909 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthrinse (single occasion)
Number of subjects: 0
Study 6585909 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthrinse (two or four times a day for 1 week)
Number of subjects: 0
Study 6585909 — intervention group
Group type: COMPARATOR
Intervention: Oxygen releasing agent (two or four times a day for 1 week)
Number of subjects: 0
Study 6585909 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 31116185 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of keratinised mucosa at both vestibular and lingual aspects
Number of subjects: 32
Study 31116185 — intervention group
Group type: COMPARATOR
Intervention: No keratinised mucosa
Number of subjects: 32
Study 31116185 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratinised mucosa height (KMH)
Number of subjects: 32
Study 29980502 — intervention group
Group type: EXPERIMENTAL
Intervention: 44-item Food Frequency e-Questionnaire (FFeQ)
Number of subjects: 223
Study 26194337 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised time filters for sleep removal
Number of subjects: 291
Study 26194337 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard time filters (9 pm-6 am, 12 am-6 am) for sleep removal
Number of subjects: 291
Study 26194337 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-wear defined as at least 60 min of consecutive zeros
Number of subjects: 291
Study 26194337 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods of sleep removal
Number of subjects: 291
Study 25306451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H)
Number of subjects: 350
Study 22017917 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g granular PGX®
Number of subjects: 10
Study 22017917 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g granular PGX®
Number of subjects: 10
Study 22017917 — intervention group
Group type: COMPARATOR
Intervention: 0 g (inert fibre)
Number of subjects: 10
Study 20473182 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network (ANN) analysis
Number of subjects: 114
Study 20473182 — intervention group
Group type: EXPERIMENTAL
Intervention: ANN approach as an advanced multivariate data processing method
Number of subjects: 114
Study 20473182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors identified by ANN
Number of subjects: 114
Study 18997197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU every other day)
Number of subjects: 14641
Study 18997197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily)
Number of subjects: 14641
Study 15820487 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 24
Study 15820487 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 24
Study 12503886 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG + progesterone (P+hCG protocol)
Number of subjects: 436
Study 12503886 — intervention group
Group type: COMPARATOR
Intervention: progesterone alone (P protocol)
Number of subjects: 436
Study 10077712 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 66
Study 10077712 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at non-acupuncture points
Number of subjects: 66
Study 10077712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 7887755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 10
Study 1557243 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-pertussis (DTP) immunization
Number of subjects: 64591
Study 1557243 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 64591
Study 3938266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (65 mg gelules, four times daily)
Number of subjects: 96
Study 3938266 — intervention group
Group type: COMPARATOR
Intervention: Quinidine arabo-galactane sulfate (QAGS, 206 mg gelules, four times daily)
Number of subjects: 96
Study 3938266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 96
Study 31361870 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled, pharmacist-led intervention
Number of subjects: 120
Study 31361870 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 31361870 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled intervention
Number of subjects: 120
Study 28349576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sending discharge letters to community pharmacists
Number of subjects: 33
Study 28349576 — intervention group
Group type: COMPARATOR
Intervention: Control group (discharge letters sent to GP only)
Number of subjects: 33
Study 26907876 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-level percutaneous fixation
Number of subjects: 90
Study 26907876 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level percutaneous fixation
Number of subjects: 90
Study 26907876 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-level open fixation
Number of subjects: 90
Study 23538918 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled cord traction
Number of subjects: 4013
Study 23538918 — intervention group
Group type: COMPARATOR
Intervention: Standard placenta expulsion
Number of subjects: 4013
Study 21284407 — intervention group
Group type: EXPERIMENTAL
Intervention: BMV 0.1% plaster
Number of subjects: 231
Study 21284407 — intervention group
Group type: COMPARATOR
Intervention: BMV 0.1% cream
Number of subjects: 231
Study 18673434 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 4 weeks
Number of subjects: 16
Study 18673434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16835424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic salpingo‐oophorectomy (555 women, 30% prior to study entry; 490 women, 27% after study entry)
Number of subjects: 1828
Study 16835424 — intervention group
Group type: COMPARATOR
Intervention: Intact ovaries (783 women, 43%)
Number of subjects: 1828
Study 15126959 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care with pamidronate
Number of subjects: 37
Study 15126959 — intervention group
Group type: COMPARATOR
Intervention: Hospital care with pamidronate
Number of subjects: 37
Study 11699342 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice for 15 minutes
Number of subjects: 0
Study 11699342 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading verses of the Bhagavad Gita in Sanskrit for 15 minutes
Number of subjects: 0
Study 11699342 — intervention group
Group type: COMPARATOR
Intervention: Reading the same verses translated in German, Spanish, or French for 15 minutes
Number of subjects: 0
Study 9334595 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.075 mg) combined with papaverine hydrochloride (50 mg), prostaglandin E1 (10 micrograms), and phentolamine mesylate (0.2 mg)
Number of subjects: 230
Study 9334595 — intervention group
Group type: COMPARATOR
Intervention: Combination of papaverine hydrochloride (50 mg), prostaglandin E1 (10 micrograms), and phentolamine mesylate (0.2 mg) without atropine sulfate
Number of subjects: 230
Study 8466313 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 24 IU for 5 days
Number of subjects: 19
Study 3721078 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive seating system
Number of subjects: 8
Study 3721078 — intervention group
Group type: COMPARATOR
Intervention: Regular sling-type wheelchair
Number of subjects: 8
Study 29423713 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytate test dentifrice (TD)
Number of subjects: 62
Study 29423713 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice (PC, 1150 ppm fluoride as NaF)
Number of subjects: 62
Study 29423713 — intervention group
Group type: COMPARATOR
Intervention: Reference dentifrice (RD, disodium pyrophosphate + 1100 ppm fluoride as NaF)
Number of subjects: 62